Meeting
2021 ASCO Annual Meeting
Optima: Optimal personalised treatment of early breast cancer using multi-parameter analysis, an international randomized trial of tumor gene expression test-directed chemotherapy treatment in a largely node-positive population.
Authors
Rob C. Stein
National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, United Kingdom
Rob C. Stein , Andreas Makris , Iain R. MacPherson , Luke Hughes-Davies , Andrea Marshall , Georgina Dotchin , David A. Cameron , Belinda Emma Kiely , Janice Tsang , Bjørn Naume , Daniel William Rea , Hege Oma Ohnstad , Peter S Hall , Stuart McIntosh , Bethany Shinkins , Chris McCabe , Adrienne Morgan , John Bartlett , Janet Dunn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
ISRCTN42400492
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS599)
DOI
10.1200/JCO.2021.39.15_suppl.TPS599
Abstract #
TPS599
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
First Author: Juerg Bernhard
Poster
2022 ASCO Annual Meeting
Ovarian function suppression is not indispensable in patients with early breast cancer who are older than age 40.
First Author: Jianqiao Xian
Poster
2022 ASCO Annual Meeting
Estradiol (E2) levels in premenopausal women with hormone receptor-positive (HR+) breast cancer (BC) on ovarian function suppression (OFS) with gonadotropin-releasing hormone agonists (GnRHa).
First Author: Megan Elizabeth Tesch
Poster
2021 ASCO Annual Meeting
Use of a high-sensitivity anti-Mullerian hormone (AMH) assay to determine ovarian function after chemotherapy for early breast cancer.
First Author: Florian Clatot